Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-1307-3p inhibitor
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral, Subcutaneous, Intravenous, Intramuscular, Inhalation, Intrathecal, Intravitreal, Parenteral
01
Overview
miR-1307-3p inhibitor is a sequence-specific oligonucleotide designed to hybridize with and inhibit the mature microRNA miR-1307-3p. In breast cancer and other malignancies, miR-1307-3p acts as an oncogenic microRNA (onco-miR) that is significantly overexpressed in tumor tissues compared to healthy tissues. By binding to miR-1307-3p, the inhibitor prevents the microRNA from suppressing its target genes (such as SMYD4, DAB2IP, and PRM2), thereby reducing cancer cell proliferation, migration, invasion, and tumor-associated angiogenesis. It is primarily utilized as a research-use-only laboratory tool to investigate the functional role of miR-1307-3p in cancer progression and chemoresistance.
- Other names
- hsa-miR-1307-3p antagomirhsa-miR1307-3p antagomirhsa-miR 1307-3p antagomirhsa-miR-1307-3p inhibitorhsa-miR1307-3p inhibitorhsa-miR 1307-3p inhibitormiR-1307-3p antagomirmiR1307-3p antagomirmiR 1307-3p antagomir
02
Targets
miR-1307-3p (microRNA 1307-3p)
Beyond the preview
Go deeper on miR-1307-3p inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-1307-3p inhibitor.